Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Should Value Investors Buy Global Partners (GLP) Stock?
10:40am, Wednesday, 03'rd Jun 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Wegovy pill maintains GLP-1 lead over Lilly rival, but weekly growth slows
08:59am, Monday, 01'st Jun 2026
Novo Nordisk's (NYSE:NVO) oral GLP-1 weight-loss drug Wegovy pill continues to outsell Eli Lilly's recently launched competing tablet, but weekly prescription growth is slowing as the market absorbs a
Lilly's Mounjaro tops other GLP-1s for some type 2 diabetes patients
07:03am, Friday, 29'th May 2026
We also report on two studies with findings that could bring eventual relief for patients still struggling with long COVID symptoms.
Lilly's GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans
03:08pm, Thursday, 28'th May 2026
That means millions more Americans may get access to Lilly's new GLP-1 pill Foundayo or the GLP-1 injection Zepbound.
Novo Nordisk faces complex GLP-1 landscape as oral launch patterns diverge from injectables
09:07am, Thursday, 28'th May 2026
Novo Nordisk's (NYSE:NVO) investor relations team presented at Deutsche Bank's European Champions Conference, with the broker maintaining its hold rating and DKK290 target price on the Danish pharma g
Wall Street Underestimates Novo Nordisk's GLP-1 Comeback
08:59am, Thursday, 28'th May 2026
Despite Wall Street skepticism, Novo Nordisk A/S is starting to catch up with Eli Lilly, the market leader in the GLP-1s market. This skepticism mainly reflects declining demand for Ozempic, as well a
CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications with Expanded Coverage Options
06:45am, Thursday, 28'th May 2026
Expanded GLP-1 options for members create a path to sustainable coverage of these important medications WOONSOCKET, R.I., May 28, 2026 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced updates t
Signos grows foothold in weight-loss wave fueled by GLP-1s with its AI health data tracking
09:07am, Wednesday, 27'th May 2026
Health tech startup Signos announced a $20 million funding round and expanded its partnership with medical device giant Dexcom. Signos makes an AI-powered glucose monitoring system designed to help wi
Novo Nordisk faces new GLP-1 rival as Eli Lilly's triple agonist sets weight-loss record
11:11am, Friday, 22'nd May 2026
Citi said Eli Lilly and Co's (NYSE:LLY) experimental obesity drug retatrutide has set a new competitive benchmark for the GLP-1 weight-loss market after a pivotal trial showed patients losing 28% of t
With a mean weight loss of 16.6%1, Wegovy® pill demonstrates best-in-class weight-loss efficacy and is the first oral GLP-1 treatment recommended by CHMP for weight management in the EU. CHMP recomme
Eli Lilly's New GLP-1 Drug Looks Like a Weight-Loss Powerhouse in New Trial
09:56am, Thursday, 21'st May 2026
Eli Lilly's investigational drug, retatrutide, delivered an average 80-week weight loss of 70 pounds at the highest dose.
Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide
09:00am, Thursday, 21'st May 2026
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada.
From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook
02:55pm, Wednesday, 20'th May 2026
Shares of Eli Lilly and Company NYSE: LLY, the world's most valuable pharmaceutical stock, started 2026 in a bad way. Near the end of April, LLY shares had fallen as much as 20%.
Novo Nordisk cautiously optimistic on key GLP-1 obesity study, says Deutsche Bank
10:46am, Wednesday, 20'th May 2026
Deutsche Bank has maintained its 'hold' rating on Novo Nordisk (NYSE:NVO) with a price target of DKK290 after hosting the Danish drugmaker's head of research and development, Martin Lange. Analyst Em
Novo Nordisk: 2 Reasons To Buy This GLP-1 Giant
05:49am, Wednesday, 20'th May 2026
I rated Novo Nordisk a Buy, trading at deep value after a 70% selloff and currently at ~10x trailing earnings. NVO's pipeline, including high-dose Wegovy, zenagamtide, and UBT251, positions it closer
